Table 4. Clinicopathological features of extranodal metastasis negative and positive groups in different current N stages in this study.
| Clinicopathological features | Current N1 stage (n=238) |
Current N2M0 stage (n=233) |
Current N3a stage with tumor size <8cm (n=233) | Current N3b stage with tumor size <8cm (n=109) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENMN | ENMP | ENMN | ENMP | ENMN | ENMP | ENMN | ENMP | ||||||
| n=231 | n=7 | P value | n=206 | n=27 | P value | n=194 | n=39 | P value | n=88 | n=21 | P value | ||
| Age (years) | ≥60 | 111 (48.1) | 5 (71.4) | 0.271 | 88 (42.7) | 15 (55.6) | 0.207 | 80 (41.2) | 16 (41.0) | 0.980 | 28 (31.8) | 8 (38.1) | 0.583 |
| <60 | 120 (51.9) | 2 (28.6) | 118 (57.3) | 12 (44.4) | 114 (58.8) | 23 (59.0) | 60 (68.2) | 13 (61.9) | |||||
| Gender | Male | 160 (69.3) | 5 (71.4) | 1.000 | 148 (71.8) | 20 (74.1) | 0.808 | 135 (69.6) | 31 (79.5) | 0.213 | 53 (60.2) | 14 (66.7) | 0.586 |
| Female | 71 (30.7) | 2 (28.6) | 58 (28.2) | 7 (25.9) | 59 (30.4) | 8 (20.5) | 35 (39.8) | 7 (33.3) | |||||
| Longitudinal location | U | 59 (25.5) | 4 (57.1) | 0.198 | 59 (28.6) | 5 (18.5) | 0.589 | 47 (24.2) | 12 (30.8) | 0.370 | 16 (18.2) | 1 (4.8) | 0.229 |
| M | 42 (18.2) | 1 (14.3) | 46 (22.3) | 6 (22.2) | 36 (18.6) | 7 (17.9) | 15 (17.0) | 5 (23.8) | |||||
| L | 129 (55.8) | 2 (28.6) | 99 (48.1) | 16 (59.3) | 110 (56.7) | 19 (48.7) | 54 (61.4) | 13 (61.9) | |||||
| UML | 1 (0.4) | 0 (0.0) | 2 (1.0) | 0 (0.0) | 1 (0.5) | 1 (2.6) | 3 (3.4) | 2 (9.5) | |||||
| Cross sectional location | Lesser | 114 (49.4) | 3 (42.9) | 0.492 | 117 (56.8) | 18 (66.7) | 0.976 | 96 (49.5) | 23 (59.0) | 0.576 | 49 (55.7) | 11 (52.4) | 0.949 |
| Greater | 19 (8.2) | 2 (28.6) | 18 (8.7) | 2 (7.4) | 11 (5.7) | 4 (10.3) | 7 (8.0) | 2 (9.5) | |||||
| Anterior | 16 (6.9) | 0 (0.0) | 8 (3.9) | 0 (0.0) | 13 (6.7) | 1 (2.6) | 5 (5.7) | 1 (4.8) | |||||
| Posterior | 27 (11.7) | 1 (0.0) | 19 (9.2) | 2 (7.4) | 17 (8.8) | 3 (7.7) | 3 (3.4) | 0 (0.0) | |||||
| Double | 36 (15.6) | 1 (14.3) | 22 (10.7) | 2 (7.4) | 24 (12.4) | 2 (5.1) | 7 (8.0) | 1 (4.8) | |||||
| Circumference | 19 (8.2) | 0 (0.0) | 22 (10.7) | 3 (11.1) | 33 (17.0) | 6 (15.4) | 17 (19.3) | 6 (28.6) | |||||
| Macroscopic type | Early stage | 30 (13.0) | 0 (0.0) | 0.307 | 6 (2.9) | 0 (0.0) | 0.768 | 7 (3.6) | 2 (5.1) | 0.675 | 2 (2.3) | 0 (0.0) | 0.260 |
| Borrmann I | 11 (4.8) | 1 (14.3) | 7 (3.4) | 2 (7.4) | 5 (2.6) | 3 (7.7) | 3 (3.4) | 0 (0.0) | |||||
| Borrmann II | 120 (51.9) | 6 (85.7) | 99 (48.1) | 14 (51.9) | 107 (55.2) | 18 (46.2) | 41 (46.6) | 10 (47.6) | |||||
| Borrmann III | 64 (27.7) | 0 (0.0) | 86 (41.7) | 9 (33.3) | 65 (33.5) | 16 (41.0) | 35 (39.8) | 6 (28.6) | |||||
| Borrmann IV | 6 (2.6) | 0 (0.0) | 8 (3.9) | 2 (7.4) | 10 (5.2) | 0 (0.0) | 7 (8.0) | 5 (23.8) | |||||
| Differentiation grade | Well | 3 (1.3) | 0 (0.0) | 0.552 | 0 (0.0) | 0 (0.0) | 0.108 | 1 (0.5) | 0 (0.0) | 0.677 | 0 (0.0) | 0 (0.0) | 0.107 |
| Moderately | 52 (22.5) | 1 (14.3) | 31 (15.0) | 1 (3.7) | 18 (9.3) | 3 (7.7) | 10 (11.4) | 0 (0.0) | |||||
| Poorly | 176 (76.2) | 6 (85.7) | 175 (85.0) | 26 (96.3) | 175 (90.2) | 36 (92.3) | 78 (88.6) | 21 (100.0) | |||||
| Tumor size (cm) | <2.5 | 30 (13.0) | 0 (0.0) | 0.296 | 14 (6.8) | 1 (3.7) | 0.181 | 12 (6.2) | 0 (0.0) | 0.113 | 3 (3.4) | 0 (0.0) | 0.059 |
| 2.5-5 | 105 (45.5) | 3 (42.9) | 72 (35.0) | 8 (29.6) | 71 (36.6) | 12 (30.8) | 28 (31.8) | 3 (14.3) | |||||
| 5-8 | 74 (32.0) | 3 (42.9) | 97 (47.1) | 12 (44.4) | 111 (57.2) | 27 (69.2) | 57 (64.8) | 18 (85.7) | |||||
| ≥8 | 22 (9.5) | 1 (14.3) | 23 (11.2) | 6 (22.2) | — | — | — | — | |||||
| Vessels/nerves invasion | Negative | 197 (85.3) | 6 (85.7) | 0.975 | 167 (81.1) | 20 (74.1) | 0.392 | 134 (69.1) | 23 (59.0) | 0.221 | 60 (68.2) | 14 (66.7) | 0.894 |
| Positive | 34 (14.7) | 1 (14.3) | 39 (18.9) | 7 (25.9) | 60 (30.9) | 16 (41.0) | 28 (31.8) | 7 (33.3) | |||||
| T stage | 1a | 19 (8.2) | 0 (0.0) | 0.104 | 0 (0.0) | 0 (0.0) | 0.840 | 1 (0.5) | 0 (0.0) | 0.356 | 0 (0.0) | 0 (0.0) | 0.411 |
| 1b | 37 (16.0) | 0 (0.0) | 5 (2.4) | 0 (0.0) | 7 (3.6) | 0 (0.0) | 1 (1.1) | 0 (0.0) | |||||
| 2a | 21 (9.1) | 0 (0.0) | 18 (8.7) | 1 (3.7) | 11 (5.7) | 2 (5.1) | 0 (0.0) | 0 (0.0) | |||||
| 2b | 26 (11.3) | 1 (14.3) | 11 (5.3) | 2 (7.4) | 14 (7.2) | 0 (0.0) | 3 (3.4) | 1 (4.8) | |||||
| 3 | 28 (12.1) | 1 (14.3) | 30 (14.6) | 5 (18.5) | 12 (6.2) | 4 (10.3) | 4 (4.5) | 0 (0.0) | |||||
| 4a | 91 (39.4) | 5 (71.4) | 130 (63.1) | 18 (66.7) | 128 (66.0) | 29 (74.4) | 68 (77.3) | 16 (76.2) | |||||
| 4b | 9 (3.9) | 0 (0.0) | 12 (5.8) | 1 (3.7) | 21 (10.8) | 4 (10.3) | 12 (13.6) | 4 (19.0) | |||||
| M stage | 0 | 229 (99.1) | 7 (100.0) | 0.805 | 206 (100.0) | 27 (100.0) | — | 179 (92.3) | 35 (89.7) | 0.600 | 70 (79.5) | 18 (85.7) | 0.521 |
| 1 | 2 (0.9) | 0 (0.0) | — | — | 15 (7.7) | 4 (10.3) | 18 (20.5) | 3 (14.3) | |||||
Abbreviations: SD: standard deviation; ENMN: extranodal metastasis negative; ENMP: extranodal metastasis positive.